We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05600322
Recruitment Status : Recruiting
First Posted : October 31, 2022
Last Update Posted : February 9, 2023
Sponsor:
Collaborators:
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Richard Wolf GmbH
Tigermed-Jyton Co., Ltd.
Information provided by (Responsible Party):
Photocure

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A study to compare Hexvix Blue light cstoscopy with standard White light cystoscopy in the detection of bladder cancer.

Condition or disease Intervention/treatment Phase
Bladder Cancer Drug: Hexaminolevulinate Hydrochloride Device: Richard Wolf Photodynamic Diagnostic Equipment (PDD) system Phase 3

Detailed Description:

A phase III, prospective, within patient controlled, multi-center study to compare Blue light cystoscopy with Hexvix and standard White light cystoscopy in the detection of bladder cancer, to evaluate the efficacy and safety of Hexvix Blue light cystoscopy in Chinese population.

Patients with suspicious or confirmed bladder cancer will participate in the trial and undergo Blue light cystoscopy with Hexvix in addition to the standard White light cystoscopy. Specific clinical questions will be asked:

  • What is the proportion of patients who have at least one specific kind of tumor found by Blue light cystoscopy with Hexvix but not by White light cystoscopy?
  • What is the proportion of patients who have at least one specific kind of lesion found by Blue light cystoscopy with Hexvix but not by White light cystoscopy?
  • What is the proportion of false positive lesions detected with Hexvix Blue light cystoscopy and White light cystoscopy?
  • What is the proportion of patients with Adverse Events (AE) during the study?
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 380 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

This is a prospective, comparative, within patient controlled, multi-center study of Hexvix Blue light cystoscopy and standard White light cystoscopy in the detection of bladder cancer. Patients with suspicious or confirmed bladder cancer will be enrolled and there will be a maximum of three regular study visits for each patient. Visit 1 is a screening visit, Visit 2 is the cystoscopic examinations and Visit 3 is the safety follow-up.

At Visit 2, enrolled patients will be instilled with 50 mL Hexvix solution in the bladder for one hour. After bladder evacuation, the inspection of the bladder and mapping of lesions seen under White light will be done. Secondly, inspection of the bladder and mapping of lesions seen under Blue light will be done. The Richard Wold PDD system (System Blue) will be used. Lesions detected will be resected or biopsied and sent to the local and central pathologists for analysis.
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Prospective, Comparative Within Patient Controlled, Multi-center Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
Actual Study Start Date : November 4, 2022
Estimated Primary Completion Date : August 31, 2023
Estimated Study Completion Date : August 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Hexvix Blue light cystoscopy
In this study, enrolled patients will undergo standard White light cystoscopy and Blue light cystoscopy following Hexvix administration. Lesions detected during the cystoscopies will be resected or biopsied.
 Drug: Hexaminolevulinate Hydrochloride
Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.
Other Name: Hexvix

Device: Richard Wolf Photodynamic Diagnostic Equipment (PDD) system
Cystoscopy in White and Blue light will be done using the Richard Wolf PDD system.
Other Name: System Blue


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Proportion of patients with histology-confirmed lesions (Ta, T1, or CIS) who have at least one such lesion found by Hexvix blue light cystoscopy but not by white light cystoscopy. [ Time Frame: 1 day (At time of cystoscopy examination) ]

Secondary Outcome Measures :
  1. Proportion of subjects with at least one additional CIS lesion detected with Hexvix blue light cystoscopy but not with white light cystoscopy. [ Time Frame: 1 day (At time of cystoscopy examination) ]
  2. The lesion detection rate of Hexvix blue light cystoscopy and white light cystoscopy for following lesion types (PUNLMP, CIS, Ta, T1, T2-T4). [ Time Frame: 1 day (At time of cystoscopy examination) ]
  3. The proportion of false positive lesions detected with Hexvix blue light cystoscopy and white light cystoscopy. [ Time Frame: 1 day (At time of cystoscopy examination) ]

Other Outcome Measures:
  1. The proportion of patients with AEs during the study. [ Time Frame: 1 week ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Volunteer to participate in clinical study; thoroughly informed, signed and dated the informed consent form; willing to follow and have the ability to complete all trial procedures.
  2. Suspicious or confirmed patients with bladder cancer.
  3. Age 18 or older.

Exclusion Criteria:

  1. Gross haematuria. (Note: Gross haematuria is defined as a heavy bladder bleed resulting in marked amounts of blood in the urine, which may visually limit cystoscopy. Where the haematuria is light, the patient should not be excluded, if in the investigator's opinion, rinsing and/or electro-cautery during cystoscopy will alleviate the possible interference with cystoscopy).
  2. Patients who have received BCG immunotherapy or intravesical chemotherapy within the past 6 weeks prior to the procedure.
  3. Porphyria.
  4. Known allergy to hexaminolevulinate hydrochloride or a similar compound.
  5. Pregnancy or breast-feeding or women who plan to become pregnant during the trial, and men or women who are unwilling to take barrier contraceptives from 2 weeks before application of investigational medication to 28 days after application of investigational medication (Note: All women of child-bearing potential must document a negative urine pregnancy test before study inclusion and use adequate contraception during the study.
  6. Participation in other clinical studies with investigational drugs either concurrently or within the last 30 days.
  7. Patient is the investigator or any sub investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
  8. Patients that the investigator assessed unsuitable to the study.
  9. Subjects with contraindications to white light cystoscopy.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05600322


Contacts
Layout table for location contacts
Contact: Lei Yu +86 13006392456 lyu@asieris.cn

Locations
Layout table for location information
China, Beijing
Cancer Hospital, Chinese Academy of Medical Sciences Not yet recruiting
Beijing, Beijing, China
Principal Investigator: Xing Nianzeng, BMed         
Peking University Third Hospital Not yet recruiting
Beijing, Beijing, China
Principal Investigator: Ma Lulin, BMed         
China, Guangzhou Province
Sun Yat-sen Memorial Hospital, Sun Yat-sen University Not yet recruiting
Guangzhou, Guangzhou Province, China
Principal Investigator: Jian Huang, BMed         
China, Hubei
Wuhan University People's Hospital Recruiting
Wuhan, Hubei, China
Principal Investigator: Song Chao, BMed         
China, Hunan
Hunan Cancer Hospital Not yet recruiting
Changsha, Hunan, China
Principal Investigator: Han Weiqing, BMed         
China, Shanghai
Zhongshan Hospital, Fudan University Not yet recruiting
Shanghai, Shanghai, China
Principal Investigator: Jianming Guo         
China, Tianjin City
The Second Hospital of Tianjin Medical University Recruiting
Tianjin, Tianjin City, China
Principal Investigator: Hu Hailong, BMed         
Sponsors and Collaborators
Photocure
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Richard Wolf GmbH
Tigermed-Jyton Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Li Han Zhong, BMed Peking Union Medical College Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Photocure
ClinicalTrials.gov Identifier: NCT05600322    
Other Study ID Numbers: PC B309/21 / YHCT-HEX-B1
First Posted: October 31, 2022    Key Record Dates
Last Update Posted: February 9, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: IPD will not be shared with other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
 Urinary Bladder Diseases
Urologic Diseases
Aminolevulinic Acid
Photosensitizing Agents
Dermatologic Agents